on August 16, 2007
Published online before print August 16, 2007, doi: 10.1161/STROKEAHA.107.488551
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 20, 2007
From the Iwate Medical University School of Medicine (A.O., M.S., T.I.), Morioka, Japan; Tohoku University Graduate School of Medicine (E.M., A.T.), Sendai, Japan; National Cardiovascular Center (K.M.), Suita, Japan; Mie University Graduate School of Medicine (W.T.), Tsu, Japan; Jichi Medical University School of Medicine (S.N.), Shimono, Japan; and Kyoto University Graduate School of Medicine (S.M.), Kyoto, Japan. * To whom correspondence should be addressed. E-mail: ta-inoue{at}ja2.so-net.ne.jp.
Background and Purpose—The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of intraarterial infusion of urokinase (UK) in patients with stroke within 6 hours of onset. Methods—Patients with ischemic stroke presenting within 6 hours of onset and displaying occlusions of the M1 or M2 portion of the middle cerebral artery on carotid angiography were randomized to the UK or control groups. Clinical outcome was assessed by the modified Rankin Scale, National Institutes of Health Stroke Scale, and Barthel Index. Results—The Independent Monitoring Committee recommended stopping the trial after approval of intravenous infusion of recombinant tissue plasminogen activator in Japan. A total of 114 patients underwent randomization, 57 patients in each group. Background characteristics were comparable between the 2 groups. The primary end point of favorable outcome (modified Rankin Scale 0 to 2) at 90 days was somewhat more frequent in the UK group than in the control group (49.1% and 38.6%, OR: 1.54, 95% CI: 0.73 to 3.23) but did not reach a significant level (P=0.345). However, excellent functional outcome (modified Rankin Scale 0 to 1) at 90 days, a preplanned secondary end point, was more frequent in the UK group than in the control group (42.1% and 22.8%, P=0.045, OR: 2.46, 95% CI: 1.09 to 5.54). There were significantly more patients with National Institutes of Health Stroke Scale 0 or 1 at 90 days in the UK group than the control group (P=0.017). The 90-day cumulative mortality was 5.3% in the UK group and 3.5% in the control group (P=1.000), and intracerebral hemorrhage within 24 hours of treatment occurred in 9% and 2%, respectively (P=0.206). Conclusions—The trial was aborted prematurely and the primary end point did not reach statistical significance. Nevertheless, the secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.
Accepted on April 4, 2007
Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke. The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan
Akira Ogawa MD;
Key words: acute • local fibrinolysis • middle cerebral artery • stroke • urokinase
Related Article:
Stroke 2007 38: 2627-2628.
This article has been cited by other articles:
 |
|
 |
|
  R. E. Latchaw, M. J. Alberts, M. H. Lev, J. J. Connors, R. E. Harbaugh, R. T. Higashida, R. Hobson, C. S. Kidwell, W. J. Koroshetz, V. Mathews, et al. Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association Stroke, November 1, 2009; 40(11): 3646 - 3678. [Full Text] [PDF]
|
|
|
|
 |
|
 A Ciccone, L Valvassori, M Ponzio, E Ballabio, R Gasparotti, M Sessa, F Scomazzoni, P Tiraboschi, R Sterzi, and the SYNTHESIS Investigators Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial JNIS, October 30, 2009; (2009) jnis.2009.001388v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Penumbra Pivotal Stroke Trial Investigators The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease Stroke, August 1, 2009; 40(8): 2761 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Novakovic, G Toth, and P D Purdy Review of current and emerging therapies in acute ischemic stroke JNIS, July 1, 2009; 1(1): 13 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver, G. W. Albers, B. Dunn, K. C. Johnston, M. Fisher, and for the STAIR VI Consortium Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials Stroke, July 1, 2009; 40(7): 2594 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.G. Nogueira, A.J. Yoo, F.S. Buonanno, and J.A. Hirsch Endovascular Approaches to Acute Stroke, Part 2: A Comprehensive Review of Studies and Trials AJNR Am. J. Neuroradiol., May 1, 2009; 30(5): 859 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hallevi, A. D. Barreto, D. S. Liebeskind, M. M. Morales, S. B. Martin-Schild, A. T. Abraham, J. Gadia, J. L. Saver, the UCLA Intra-Arterial Therapy Investigators, J. C. Grotta, et al. Identifying Patients at High Risk for Poor Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1780 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Saver and J. Gornbein Treatment effects for which shift or binary analyses are advantageous in acute stroke trials Neurology, April 14, 2009; 72(15): 1310 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arnold, M. Steinlin, A. Baumann, K. Nedeltchev, L. Remonda, S. J. Moser, M.-L. Mono, G. Schroth, H. P. Mattle, and R. W. Baumgartner Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature Stroke, March 1, 2009; 40(3): 801 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bose, H. Henkes, K. Alfke, W. Reith, T.E. Mayer, A. Berlis, V. Branca, S. P. Sit, and for the Penumbra Phase 1 Stroke Trial Investigator The Penumbra System: A Mechanical Device for the Treatment of Acute Stroke due to Thromboembolism AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1409 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Quinn and K. R. Lees Advances in Emerging Therapies 2007 Stroke, February 1, 2008; 39(2): 255 - 257. [Full Text] [PDF]
|
|